Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.

Research output: Contribution to journalArticle

Abstract

This study explored the feasibility and toxicity of individualized toxicity-titrated 6-mercaptopurine (6MP) dose increments during post-remission treatment with High-dose methotrexate (HDM) (5000 mg/m(2) , ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m(2) per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m(2) per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.

Details

Authors
  • Thomas L Frandsen
  • Jonas Abrahamsson
  • Birgitte Lausen
  • Kim Vettenranta
  • Mats Heyman
  • Michael Behrentz
  • Anders Castor
  • Peder S Wehner
  • Britt-Marie Frost
  • Elisabeth W Andersen
  • Kjeld Schmiegelow
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology
Original languageEnglish
Pages (from-to)244-247
JournalBritish Journal of Haematology
Volume155
Publication statusPublished - 2011
Publication categoryResearch
Peer-reviewedYes